INPLASY PROTOCOL

To cite: Zhang et al. Coagulopathy in patients with Coronavirus Disease 2019（COVID-19）: a systematic review and meta-analysis. Inplasy protocol 202050004. doi: 10.37766/inplasy2020.5.0004

Received: 02 May 2020

Published: 02 May 2020

Corresponding author:
Xiaolin Zhang

zhangxiaolin0001@126.com

Author Affiliation:
Peking University First Hospital

Support: **2018SF058**

Review Stage at time of this submission: **Preliminary searches.**

Conflicts of interest:
The authors declare that they have no conficts of interest.

Coagulopathy in patients with Coronavirus Disease 2019 (COVID-19)：a systematic review and meta-analysis

Zhang, X[1]; Yang, X[2]; Jiao, H[3]; Liu, X[4].

Review question / Objective: **We compare the coagulation parameters between severe and mild cases of COVID-19 patients, including Platelet count (PLT),activated partial thromboplastin time (APTT), prothrombin time (PT) and D-dimer (D-D)levels.Coagulation parameters between surviors and non-surviors are also explored. We conducted meta regression to explore the risk factor of COVID19-related coagulopathy.**
Condition being studied: **COVID19 is widely spread and poses a critical threat to global health.Coagulopahy in severe patients of COVID19 have been reported in several studies.Emerging evidence shows that severe COVID19 can be complicated with coagulopathy,with high risk of disseminated intravascular coagulation,venous thromboembolism and other thrombotic events.We aim to conduct a systemitic review and meta-analysis of coagulopathy in patients with COVID19. Coagulopathy may be an indication of severity and poor prognosis.Clinicans should pay more attention to coagulopathy in COVID19.**

INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 02 May 2020 and was last updated on 02 May 2020 (registration number INPLASY202050004).

INTRODUCTION

Review question / Objective: **We compare the coagulation parameters between severe and mild cases of COVID-19 patients,including Platelet count (PLT),activated partial thromboplastin time (APTT), prothrombin time (PT) and D-dimer (D-D)levels.Coagulation parameters between surviors and non-surviors are also explored. We conducted meta regression to explore the risk factor of COVID19-related coagulopathy.**

Condition being studied: **COVID19 is widely spread and poses a critical threat to global health. Coagulopahy in severe patients of COVID19 have been reported in several**

studies.Emerging evidence shows that severe COVID19 can be complicated with coagulopathy, with high risk of disseminated intravascular coagulation, venous thromboembolism and other thrombotic events.We aim to conduct a systemitic review and meta-analysis of coagulopathy in patients with COVID19. Coagulopathy may be an indication of severity and poor prognosis.Clinicans should pay more attention to coagulopathy in COVID19.

METHODS

Search strategy: 1) "Covid-19" OR "2019 novel coronavirus infection" OR "SARS-CoV-2"AND"characteristics" (2) "Covid-19" OR "2019 novel coronavirus infection" OR "SARS-CoV-2" AND "coagulation"OR"coagulopathy" (3) "Covid-19" OR "2019 novel coronavirus infection" OR "SARS-CoV-2"AND"coagulation".

Participant or population: Patients with COVID19.

Intervention: Observational study:serve group.

Comparator: Mild group.

Study designs to be included: We included all research articles in adult patients diagnosed with COVID-19 with information on coagulation and clinical grouping or outcome of the cl.

Eligibility criteria: Articles other than original research(e.g., review articles, letters, or commentaries); original research with samples below 20 or case reports and series; articles on research in pediatric populations.

Information sources: PubMed, EmBase, Cochrane, WanFang Database and CNKI, medRxiv (https://www.medrxiv.org), SSRN(https://www.ssrn.com).

Main outcome(s): The coagulation parameters including PLT, PT, APTT, D-dimer are evaluated.

Quality assessment / Risk of bias analysis: All the search results were evaluated according to Newcastle-Ottawa Scale.

Strategy of data synthesis: Meta-analysis is carried out using Stata14.0 software. Heterogeneity among studies is tested using the Cochran Chi-square test and I 2. When I 2 is less than 50% a fixed-effects model is used and when I2 is more than 50%, a random-effects model is used.

Subgroup analysis: We conduct subgroup to patients from China and other country.

Sensibility analysis: Sensitivity analysis is conducted to determine the source of heterogeneity by excluding one study at a time.

Language: English.

Country(ies) involved: China.

Keywords: COVID19, coagulopathy, coagulation.

Contributions of each author:
Author 1 - Xiaolin Zhang.
Author 2 - Xue Yang.
Author 3 - Hongmei Jiao.
Author 4 - Xinmin Liu.